The effect of lovastatin (LOV), the inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, on linoleic acid (LA, label associated with LA and increased the percentage of label in the 20:4n-6 and the 22:5n-6 fractions. In Hep G2 but not MM6 cells, this effect was fully reversible by means of coincubation with mevalonic acid (500 gM), but not with cholesterol or lipoproteins. In both cell lines, the LOV-mediated increase in LA desaturation resulted in dose-dependent reductions of LA and elevations of AA in cellular phospholipids. The lipids secreted by LOV-treated Hep G2 cells were also enriched in arachidonic acid (AA). In the MM6 cells, LOV increased release of thromboxane upon stimulation with the calcium ionophore A23187. In summary, our findings of higher LA desaturation and AA enrichment of lipids secreted by the Hep G2 cells suggest that LOV treatment may increase the delivery of AA from the liver to extrahepatic tissues. The changes in membrane fatty acid composition can influence a variety of cellular functions, such as eicosanoid synthesis in monocytic cells. The mechanism appears to be related to the reduced availability of intermediates of cholesterogenesis. (J. Clin. Invest. 1994. 93:195-203.) Key words: fatty acids * 3-hydroxy-3-methyl coenzyme A reductase inhibitor-lipoproteins * mevalonatethromboxane
Introduction
Inhibitors of 3-hydroxy-3-methyl-glutaryl CoA(HMGCoA)' reductase, such as (LOV), are widely used in the treatment of hypercholesterolemia. They suppress the early conversion step of HMGCoA to mevalonate (MVA) and thus the subsequent synthesis of cholesterol and its precursors. Their main site of action is the liver, where inhibition of cholesterol synthesis leads to the desired up-regulation of LDL receptor-mediated evaporated under N2 and the salt was immediately reconstituted with 2.5 mM BSA dissolved in RPMI 1640 to yield a 5 mM fatty acid solution. The pH was adjusted to 7.4 with 1 N NaOH and aliquots were stored in liquid N2.
Preparation of lipoproteins. LDL was isolated from normolipemic fasting plasma in the density interval 1.021-1.063 by sequential preparative ultracentrifugation and dialyzed against 20 liters of buffer containing 9 g/liters Na Cl, 0.09 g/liters EDTA, and 0.05 g/liters chloramphenicol, pH 7.4. Acetyl LDL was prepared as described in Basu et al. (16) , washed, and concentrated in the above buffer by means of Centricon filters (CF25, Amicon, Witten, FRG). The extent of LDL acetylation was assessed by agarose-gel electrophoresis (Ciba Corning, Medfield, MA). Protein content was determined (17) , and lipoproteins were filter-sterilized (0.22 Mm), stored at 40C, and used within 1 were treated with LOV 0.04-10 uM or DMSO (5-6 175-cm2 flasks per treatment) for a total of 8 d. On day 4, cells were given fresh growth medium containing 10gM albumin-bound LA. On day 6, growth medium was removed and cells were washed three times with 30 ml of Dulbecco's PBS and once with serum-free DME. After washing, 30 ml of fresh serum-free DME was added and harvested after 24 h. This procedure was repeated on day 7. The harvested medium was supplemented with EDTA (1 mg/ml) and gentamycin sulfate (0.1 mg/ml), centrifuged at 1,000 g for 30 min at 40C to remove cell debris, and stored at 4VC. Media from the two harvests were pooled and concentrated to minimal volumes by ultrafiltration (Amicon stirred cell, PM30 membranes). Concentrates were lyophilized and total lipids were extracted with chloroform/methanol (2:1 ). Phospholipid, triglyceride, and cholesterol ester fractions were separated on aminopropyl columns ( 18) , and fatty acids were quantified as described above. Determination of thromboxane release. Freshly passaged MM6 cells were incubated with LOV, LA, MVA, and lipoproteins as described later in detail. Medium was removed after centrifugation (800 rpm x 5 min) and cells were resuspended at 106 cells/ml in a buffer containing 20 mM Hepes, 120 mM NaCI, 2.7 mM KCl, 1.4 mM MgSO4, 1 mM CaCl2, 1.4 mM KH2PO4, 25 mM NaHCO3, and 10 mM glucose, pH 7.4. Cells were then stimulated (37°C, 5 min) with ionophore A23 187(1 gM in DMSO) or DMSO alone (final concentration < 0.1%). Stimulation was terminated at 4°C, and thromboxane release was determined in 50-,ul aliquots of supernatant using a highly specific and sensitive antiserum against TXB2 (gift of Dr. J. Levine, Brandeis University, Waltham, MA) and [3H]TXB2 as a tracer (20) .
Determination of cellular protein and lipids. Aliquots of Hep G2 and MM6 cells were washed and extracted with hexane/isopropanol (3:2) as described above. Total cellular cholesterol (21), phospholipid (22) , and triglyceride (kit no 470694, Boehringer Mannheim GmbH, Mannheim) levels were determined in aliquots of the total lipid extract.
Protein of extracted cell pellets was mmasured as in Rodriguez-Vico et al. (23) .
Statistics. Unless otherwise stated, results are expressed as means±SEM. Statistical significance was assessed by means of Student's t test for paired and unpaired data and analysis of variance as appropriate.
Results
LOV effects on cellular phospholipidfatty acid composition. In MM6 cells supplemented with LA (10 I M), LOV (0.4, 4, 10, and 20 ,uM) produced a statistically significant, dose-dependent decrease in cellular phospholipid 1 8:2n-6 content (10.5±0.8% in control cells vs. 5.6±0.5% in cells treated with 20,M LOV) ( Table I ). In contrast, the relative AA content was increased from 9.7±0.5% in control cells to 12.9±0.3% and 14.9±0.4% in cells treated with 10 and 20 MM LOV, respectively (Table I) . At the two highest LOV doses, significant increases in the minor longer-chain, more desaturated derivatives of AA, 22:4n-6 and 22:5n-6, were also observed. (Table II) . Lovastatin had no effect on the relative content ofphospholipid saturated and monoene fatty acids in the two cell lines studied (Tables I and II) . The levels of n-3 fatty acids were also not altered by LOV, most likely due to the low levels of the precursor (1 8:3n-3) present.
The effect of LOV (10 MM, 72 h) on cellular phospholipid composition was also examined in Hep G2 cells coincubated with LDL ( 100 ,g/ml, last 24 h). LDL incubation produced a large increase in LA content in cellular phospholipids (Fig. 2 B) . In Reversibility ofthe LO V effect on LA metabolism. In order to explore the possible mechanisms behind the LOV-induced changes in LA metabolism, their reversibility after the coincubation with MVA, cholesterol, or lipoproteins was examined in both cell lines. Our results indicate differences in the response to this treatment between the two cell lines.
In the Hep G2 cell line, the LOV effect on LA desaturation could be reversed by means of coincubation with MVA (500 MM, Fig. 3 Thromboxane synthesis in the MM6 cell line. To investigate the potential functional consequences of a LOV-mediated rise in cellular AA levels, its effect on thromboxane synthesis was examined in the MM6 cell line. LOV increased the thromboxane synthesis in A23 187-stimulated cells in a dose-dependent manner (Fig. 4) . Thromboxane release was also marginally higher after treatment with 20 ,M LOV in unstimulated cells (5 min, DMSO 0.1%, data not shown). This effect could be reversed by means ofcoincubation with 500 ,gM MVA (Fig.   5 ), while mevalonic acid added to control cells had no influence on thromboxane synthesis (data not shown). In contrast, cells incubated with LOV (10 1AM, 72 h) and LDL (100 ,ug/ml) released more thromboxane than cells treated with LOV alone (Fig. 5) . Preliminary results indicate that LDL or acetyl LDL alone also stimulate thromboxane release in control cells (data not shown).
Influence ofLO Von cellular lipids. In the Hep G2 cells, 10 and 40 ,M LOV (72 h) induced a dose-dependent accumulation of cellular triglycerides, while cellular phospholipids were marginally elevated at 40 uM LOV, P < 0.10 (Table VII) . In contrast, the cellular cholesterol content of both Hep G2 (Table VII) and MM6 (data not shown) cells was not affected.
Influence ofLO V on cell proliferation and viability. In the MM6 cell line, LOV produced a dose-dependent suppression ofcellular proliferation which was statistically significant at the 20,MM dose level (Fig. 6 ). Cell proliferation was partially recovered by means ofcoincubation with MVA (500,MM), while cell proliferation after LDL ( 100 Mg/ml) was further reduced. HDL triglyceride (6) in patients undergoing HMGCoA reductase inhibitor therapy has been reported. The present study was undertaken to examine the effects of LOV on the metabolism of LA in the human hepatoma (Hep G2) and monocytic MM6 cell lines. We demonstrate that LOV increases the desaturation of LA and thus the cellular phospholipid content of AA. The higher availability of cellular AA in turn results in higher AA content of lipids secreted by the Hep G2 cells and increased release of thromboxane in the MM6 cells.
HMGCoA reductase inhibitors may influence fatty acid desaturase activity secondary to their specific inhibition of the cholesterol biosynthetic pathway or through their nonspecific action on systems related to drug metabolism. With respect to the first possibility, manipulation of membrane cholesterol content is known to have profound effects on membrane fluidity and function of membrane-associated enzymes (1, 2) . Increased microsomal membrane fluidity, AA content and enhanced A 5 and 6 desaturase activities have been documented in liver microsomes of rats fed a sterol-free diet (9) . The feeding of cholesterol-rich diets, on the other hand, can lead to decreased liver microsomal A 5 and 6 desaturase activity and AA content (8, 10, 26) . Although our findings of increased desaturation of LA in LOV-treated cells tend to parallel the above results, the effect observed does not appear to be closely related to cellular cholesterol content. As previously described in other cell culture systems (27) , we find no significant reductions in cellular cholesterol levels after LOV treatment. We assume that the reduction of de novo cholesterol synthesis, produced by LOV, is sufficiently compensated for by increased uptake ofcholesterol from the cell culture media, both ofwhich contained 10% FCS. In support of this, both the Hep G2 (14) and MM6 (our own observation) cell (28, 29) , chemotaxis (27) , and signal transduction (28, 30) . With respect to the later metabolites of cholesterogenesis, dolichol phosphates are required for glycoprotein synthesis, while ubiquinone and heme are involved in the electron transport chain (4).
In our experiments, the LOV-mediated changes in LA metabolism in the Hep G2 cell line were completely reversed by the addition of MVA. In the MM6 cell line, the LOV-induced increase in thromboxane release was reduced with MVA, although under the experimental conditions used, the conversion of LA to AA was not. Coincubation of LOV-treated cells with LDL, on the other hand, enhanced thromboxane release. Similar effects of LDL on thromboxane release has been seen in endothelium (31 ) and platelets (32) . Taken together, our data strongly suggest that a decrease in the availability ofone or more of the early intermediates of cholesterogenesis were responsible for the observed cellular effects ofLOV on the microsomal desaturation of PUFA and the subsequent synthesis of eicosanoids.
Treatment with LOV and related compounds results in a marked accumulation of the microsomal inactive HMGCoA reductase enzyme and proliferation of the endoplasmic reticulum (33) . Peroxisomal hyperplasia with concomitant increases in fatty acid synthesis and triglyceride and phospholipid accumulation in cultured human keratinocytes after LOV has also been recently reported (34). We also observe accumulation of cellular triglyceride and increased uptake of fatty acid into the triglyceride lipid fraction in our LOV-treated Hep G2 cells. Thus, LOV may act similarly to other lipid-lowering drugs such as the fibrates, for which peroxisomal hyperplasia and induction of endoplasmic reticulum enzymes (35, 36) , as well as perturbations in fatty acid metabolism (37-39) have been reported. Induction of fatty acid desaturation in proliferating hepatic endoplasmic reticulum in response to treatment with polychlorinated biphenyls suggests that fatty acid desaturases are cytochrome P450-dependent monooxygenases (40) . Cytochrome P450 enzymes are also responsible for the oxidative metabolism of lovastatin (41 ) . Thus HMGCoA reductase inhibitors may stimulate LA desaturation through the induction of the endoplasmic reticulum. Recently, however, no nonspecific activation of several cytochrome P450-linked enzymes has been detected in rats treated with simvastatin, despite elevations in microsomal AA acid content (42) . As in the present study, some of the above cited inhibitor-induced effects in human keratinocytes were reversible with MVA as well as with lipoproteins (34). Thus even in this case, LOV would appear to act specifically via its suppression of the cholesterol synthesis pathway.
The hepatoma Hep G2 cell line, used extensively in studies of liver lipid metabolism ( 14) , is an appropriate cell model in the study of effects of HMGCoA reductase inhibitors in the liver, the target organ of these drugs. We show increases in arachidonic acid content in lipids secreted by the Hep G2 cells at lovastatin doses equivalent to plasma LOV concentrations of patients undergoing LOV therapy (43) . Even higher transient concentrations may be present in the liver, where LOV is cleared in the first passage. Our findings in this cell line support in vivo studies (5, 42) that indicate that the use of HMGCoA inhibitors leads to an increased availability of AA in hepatic and extrahepatic tissues. Our findings in Hep G2 cells coincubated with LDL also suggest that the LOV-mediated increase in hepatic lipoprotein clearance, and thus increased delivery of LA-rich cholesterol ester to the liver cell, may contribute to this effect.
Our findings in the MM6 cell line, considered to be a good model for the peripheral blood monocyte ( 15) , further suggest potential functional consequences of LOV in the periphery, namely the increased synthesis of thromboxane. This may be the consequence of a direct LOV action in the periphery or an increased supply ofAA via lipoproteins secreted by the liver, to eicosanoid-producing tissues.
In summary, the present in vitro finding of increased conversion of LA to AA by the Hep G2 and MM6 cells, and the concomitant increase in AA content of lipids secreted by the Hep G2 cells support clinical findings ofincreased systemic AA levels in patients undergoing HMGCoA reductase inhibitor therapy. At the cellular level, this effect appears to be strongly linked to a decrease in the availability of early nonsterol intermediates of the cholesterol synthesis pathway, and thus possibly to the decreased prenylation of cellular proteins. This may have impact on the composition of cellular fatty acids and on the systemic synthesis of eicosanoids. The elucidation of the mechanisms involved, and their physiological significance are worthy of further study.
